A central role for protein kinase c overactivity in diabetic glomerulosclerosis: Implications for prevention with antioxidants, fish oil, and ACE inhibitors

Medical Hypotheses

Volumn 50, Issue 2, 1998, Pages 155-165

  Mccarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; ANTIOXIDANT; ASCORBIC ACID; DIACYLGLYCEROL KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; GAMMA LINOLENIC ACID; HEPARAN SULFATE; NITRIC OXIDE; PHOSPHATIDATE PHOSPHATASE; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SELENIUM; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIPID PEROXIDATION; MESANGIUM CELL; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

GLOMERULUS;

EID: 0031934310     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90202-X     Document Type: Article

References (166)

1. Craven P A, DeRubertis F R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989; 83: 1667-1675.
2. Craven P A, Davidson C M, DeRubertis F R. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990; 39: 667-674.
3. Ayo S H, Radnik R, Garoni J A et al. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991; 261: F571-F577.
4. Inoguchi T, Battan R, Handler E et al. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci 1992; 89: 11059-11063.
5. Inoguchi T, Xia P, Kunisaki M et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 1994; 267: E369-E379.
6. DeRubertis F R, Craven P A. Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994; 43: 1-8.
7. Ishii H, Jirousek M R, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728-731 .
8. Mogensen C E, Christensen C K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311:89-93.
9. Steffes M W, Østerby R, Chavers B, Mauer S M. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989; 38: 1077-1081.
10. Okuda S, Languino L R, Ruoslahti E, Border W A. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990; 86: 453-462.
11. Border W A, Okuda S, Languino L R et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346: 371-374.
12. Border W A, Noble N A, Yamamoto T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-364.
13. Border W A, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
14. Yamamoto T, Nakamura T, Noble N A et al. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci 1993; 90: 1814-1818.
15. Ziyadeh F N, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93: 536-542.
16. Sharma K, Ziyadeh F N. The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994; 266: F829-F842.
17. Sharma K, Ziyadeh F N. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes 1995; 44: 1139-1146.
18. Sharma K, Jin Y, Guo J, Ziyadeh F N. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertropy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530.
19. Akhurst R J, Fee F, Balmain A. Localized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis. Nature 1988; 331: 363-365.
20. Kim S-J, Denhez F, Kim KY et al. Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor-β1 and phorbol ester occurs through the same target sequences. J Biol Chem 1989; 264: 19373-19378.
21. Asiedu C K, Scotto L, Assoian R K, Ehrlich M. Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-β1 gene. Biochim Biophys Acta 1994; 1219: 55-63.
22. Kagami S, Border W A, Miller D E, Noble N A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
23. Studer R K, Craven P A, DeRubertis F R. Thromboxane stimulation of mesangial cell fibronectin synthesis is signaled by activation of protein kinase C and is modulated by cGMP. J Am Soc Nephrol 1993; 4: 458.
24. Studer R K, Craven P A, DeRubertis F R. Low-density lipoprotein (LDL) stimulation of rat mesangial cell (MC) fibronectin synthesis (FbSn) is dependent on activation of protein kinase C (PKC) J Am Soc Nephrol 1993; 4: 666.
25. Van Obberghen-Schilling E, Roche N S, Flanders K C et al. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J Biol Chem 1988; 263: 7741-7746.
26. Hostetter T H, Rennke H G, Brenner B M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
27. Zatz R, Meyer T W, Rennke H G, Brenner B M. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci 1985; 82: 5963-5967.
28. Bjørck S, Nyberg G, Mulec H et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986; 293: 471-479.
29. Zatz R, Dunn B R, Meyer T W et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
30. Myers B D, Meyer T W. Angiotensin-converting enzyme inhibitors in the prevention of experimental diabetic glomerulopathy. Am J Kidney Dis 1989; 13: 20-24.
31. Walker J D, Dodds R A, Murrells T J et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; ii: 1411-1415.
32. Ihle B U, Becker G J, Whitworth J A et al. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989; 321: 1773-1777.
33. Okuda S, Nakamura T, Yamamoto T et al. Dietary protein restriction rapidly reduces transforming growth factor β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci 1991; 88: 9765-9769.
34. Kakinuma Y, Kawamura T, Bills T et al. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46-55.
35. Lewis E J, Hunsicker L G, Bain R P et al. The effect of antiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
36. Hirschberg R R, Zipser R D, Slomowitz L A, Kopple J D. Glucagon and prostaglandins are mediators of amino acid-induced rise in renal hemodynamics. Kidney Int 1988; 33: 1147-1155.
37. Rosenberg M E, Kren S M, Hostetter T H. Effect of dielary protein on the renin-angiotensin system in subtotally nephreclomized rats. Kidney Int 1990; 38: 240-248.
38. Riser B L, Cortes P, Zhao X et al. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 1992; 90: 1932-1943.
39. Riser B L, Grondin J M, Cortes P et al. Mesangial cell stretch stimulates the secretion and activation of transforming growth factor beta 1 but not TGF-β2/TGF-β3 (Abstract). J Am Soc Nephrol 1993; 4: 663.
40. Schambelan M, Blake S, Sraer J et al. Increased prostaglandin production by glomeruli isolated from rats with streptozolocin-induced diabetes mellitus. J Clin Invest 1985; 75: 404-412.
41. Kasiske B L, O'Donnell M P, Keane W F. Glucose-induced increases in renal hemodynamic function: possible modulation by renal prostaglandins. Diabetes 1985; 34: 360-364.
42. Craven P A, Caines M A, DeRubertis F R. Sequential alterations in glomeralar prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism 1987; 36: 95-103.
43. 2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats. Diabetes 1988; 37: 429-435.
44. Sakurai T, Tsuchiya S. Superoxide production from nonenzymatically glycated protein. FEBS Lett 1988; 236: 406-410.
45. Baynes J W. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
46. Oberley L W. Free radicals and diabetes. Free Radical Biol Med 1988; 5: 113-124.
47. Sato Y, Hotta N, Sakamoto N et al. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979; 21: 104-107.
48. Kaji H, Kurasaki M, Ito K et al. Increased lipoperoxide value and glutathione peroxidase activity in blood plasma of type 2 (non-insulin-dependent) diabetic women. Klin Wochenschr 1985; 63: 765-768.
49. Shasby D M, Yorek M, Shasby S S. Exogenous oxidants initiate hydrolysis of endothelial cell inositol phospholipids. Blood 1988; 72: 491-499.
50. Rossi M A, Garramone A, Dianzani M U. Effect of 4-hydroxy-2,3-trans-nonenal, a lipid peroxidation product, on hepatic phospholipase C. Med Sci Res 1989; 17: 257-258.
51. Rossi M A, Fidale F, Garramone A et al. Effect of 4-hydroxy-alkenals on hepatic phosphatidylinositol-4,5-bisphosphate-phospholipase C. Biochem Pharm 1990; 39: 1715-1719.
52. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-496.
53. Tran K, Proulx P R, Chan A C. Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity. Biochim Biophys Acta 1994; 1212: 193-202.
54. Lee I-K, Koya D, Ishii H, King G L. Vitamin E (vit E) prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. Diabetes 1996; 45(Suppl 2): 64A.
55. Setty B N Y, Graeber J E, Stuart M J. The mitogenic effect of 15- and 12-hydroxyeicosatetraenoic acid on endothelial cells may be mediated via diacylglycerol kinase inhibition. J Biol Chem 1987; 262: 17613-17622.
56. McCarty M F. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. Med Hypotheses 1996; 46: 191-221.
57. Koya D, Lee I-K, Ishii H, Bursell, S-E. Vitamin E normalized glomerular hyperfiltration and protein kinase C activation by increasing diacylglycerol kinase in diabetic rats. Diabetes 1996; 45(Suppl 2): 205A.
58. Beyer-Mears A, Cruz E, Kowluru R et al. Short term effects of vitamin C plus E on diabetic albuminuria and proteinuria. Diabetes 1996; 45(Suppl 2): 206A.
59. Douillet C, Tabib A, Bost M et al. A selenium supplement associated or not with vitamin E delays early renal lesions in experimental diabetes in rats. Proc Soc Exp Biol Med 1996; 211: 323-331.
60. Trachtman H, Futterweit S, Bienkowski R S. Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells. Biochem Biophys Res Commun 1993; 191: 759-765.
61. Trachtman H, Futterweit S, Prenner J, Hanon S. Antioxidants reverse the antiproliferative effect of high glucose and advanced glycosylation end products in cultured rat mesangial cells. Biochem Biophys Res Commun 1994; 199: 346-352.
62. Tamsma J T, van den Born J, Bruijn J A et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37: 313-320.
63. Au Y P T, Kenagy R D, Clowes M M, Clowes A W. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis 1993; 23(Suppl 1): 177-182.
64. Pukac L A, Ottlinger M E, Karnovsky M J. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J Biol Chem 1992; 267: 3707-3711.
65. Castellot J J Jr, Hoover R L, Harper P A, Karnovsky M J. Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation. Am J Pathol 1985; 120: 427-435.
66. Olson J L. Role of heparin as a protective agent following reduction of renal mass . Kidney Int 1984; 25: 376-382.
67. Craven P A, Studer R K, DeRubertis F R. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats J Clin Invest 1994; 93: 311-320.
68. Craven P A, Studer R K, DeRubertis F R. Impaired nitric oxide release by glomeruli from diabetic rats. Metabolism 1995; 44: 695-698.
69. Lewis M J, Henderson A H. A phorbol ester inhibits the release of endothelium-derived relaxing factor. Eur J Pharm 1987; 137: 167-171.
70. Rubanyi G M, Desiderio D, Luisi A et al. Phorbol dibutyrate inhibits release and action of endothelium-derived relaxing factor(s) in canine blood vessels. J Pharm Exp Ther 1989; 249: 858-863.
71. Studer R K, Craven P A, DeRubertis F R. Thromboxane stimulation of mesangial cell fibronectin synthesis is signaled by activation of protein kinase C and is modulated by cGMP. J Am Soc Nephrol 1993; 4: 458.
72. Raij L, Shultz P J. Endothelium-derived relaxing factor, nitric oxide: effects on and production by mesangial cells and the glomerulus. J Am Soc Nephrol 1993; 2: 1435-1441.
73. Trachtman H, Futterweit S, Singhal P. Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun 1995; 207: 120-125.
74. Gabbai F B, Garcia G E, Blantz R C, De Nicola L. Role of nitric oxide in glomerular physiology and pathophysiology. Adv Nephrol 1995; 24: 3-18.
75. Bucala R, Tracey K J, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
76. Greene D A, Sima A A F, Stevens M J et al. Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 1993; 9: 189-217.
77. Moreau P, Yamaguchi N, de Champlain J. Increased activity in the nitric oxide pathway during chronic euglycemic hyperinsulinemia in the rat. J Hypertens 1993; 11(Suppl 5): S270-S271.
78. Scherrer U, Randin D, Vollenwieder P et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.
79. Petrie J R, Ueda S, Webb D J et al. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996; 93: 1331-1333.
80. Steinberg H O, Brechtel G, Johnson A et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179.
81. Dzúrik R, Spustová V, Janeková K. The prevalence of insulin resistance in kidney disease patients before the development of renal failure. Nephron 1995; 69: 281-285.
82. 2 in cultured mesangial cells. Am J Physiol 1988; 24: F1059-F1069.
83. Spurney R F, Onorato J J, Albers F J, Coffman T M. Thromboxane binding and signal transduction in rat glomerular mesangial cells. Am J Physiol 1993; 264: F292-F299.
84. Pfeilschifter J, Bauer C. Pertussis toxin abolishes angiotensin II-induced phosphoinositide hydrolysis and prostaglandin synthesis in rat renal mesangial cells. Biochem J 1986; 236: 289-294.
85. Craven P A, Melhem M F, DeRubertis F R. Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 1992; 42: 937-946.
86. Wilkes B M, Solomon J, Maita M, Mento P F. Characterization of glomerular thromboxane receptor sites in the rat. Am J Physiol 1989; 256: F1111-F1116.
87. Hora K, Oguchi H, Furukawa T et al. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Nephron 1990; 56: 297-305.
88. Craven P A, DeRubertis F R. Suppression of urinary albumin excretion in diabetic rats by 4′(imidazol-1-yl) acetophenone, a selective inhibitor of thromboxane synthesis. J Lab Clin Med 1990; 116: 469-478.
89. Giustina A, Bossoni S, Cimino A et al. Picotamide, a dual TXB synthetase inhibitor and TXB receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes 1993; 42: 178-182.
90. Anderson S, Jung F F, Ingelfinger J R. Renal reninangiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486.
91. Weber P C, Fischer S, von Schacky C et al. Dietary omega-3 polyunsaturated fatty acids and eicosanoid formation in man. In: Simopoulos A P, Kifer R R, Martin R E, eds. Health Effects of Polyunsaturated Fatty Acids in Seafoods. Orlando, FL: Academic Press, 1986: 49-60.
92. Sinha A K, Scharschmidt L A, Neuwirth R et al. Effects of fish oil on glomerular function in rats with diabetes mellitus. J Lipid Res 1990; 31: 1219-1228.
93. Kenny D, Warliter D C, Pleuss J A et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol 1992; 70: 1347-1352.
94. Locher R, Sachinidis A, Steiner A et al. Fish oil affects phosphoinositol turnover and thromboxane A metabolism in cultured vascular muscle cells. Biochim Biophys Acta 1989; 1012: 279-283.
95. McCarty M F. Fish oil may impede tumor angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1995; 46: 107-115.
96. Yared A, McPeak R A, Ichikawa I et al. Attenuated renal vascular reactivity to angiotensin II in rats fed ω̧3 versus ω̧6 unsaturated fatty acids (UFA). Kidney Int 1990; 37: 360.
97. Schmitz P G, O'Donnell M P, Kasiske B L, Keane W F. Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. J Lab Clin Med 1991; 118: 129-135.
98. Düsing R, Struck A, Göbel B O et al. Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 1990; 38: 315-319.
99. Jensen T, Stender S, Goldstein K et al. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med 1989; 321: 1572-1577.
100. Shimizu H, Sato N, Tanaka Y et al. Effect of eicosapentaenoic acid ethyl [sic] on urine albumin excretion in NIDDM. Diabetes Care 1993; 16: 1406-1408.
101. Bennett W M, Walker R G, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two year prospective trial. Clin Nephrol 1989; 31: 128-131.
102. Stoof T J, Korstanje M J, Bilo H J G et al. Does fish oil protect renal function in cyclosporin-treated psoriasis patients? J Intern Med 1989; 226: 437-441.
103. Bilo H J G, Homan van der Heide J J, Gans ROB, Donker AJM. Omega-3 polyunsaturated fatty acids in chronic renal insufficiency. Nephron 1991; 57: 385-393.
104. Homan van de Heide J J, Bilo H G J, Donker J M et al. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993; 329: 769-773.
105. Donadio J V, Bergstralh E J, Offord K P et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331: 1194-1199.
106. De Caterina R, Endres S, Kristensen S D, Schmidt E B. n-3 fatty acids and renal diseases. Am J Kidney Dis 1994; 24: 397-415.
107. Fernandes G. Dietary lipids and risk of autoimmune disease. Clin Immunol Immunopathol 1994; 72: 193-197.
108. McVeigh G E, Brennan G M, Johnston G D et al. Dietary fish oil augments nitric oxide production or release in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 33-38.
109. Marsh J B, Topping D L, Nestel P J. Comparative effects of dietary fish oil and carbohydrate on plasma lipids and hepatic activities of phosphatidate phosphohydrolase, diacylglycerol acyltransferase and neutral lipase activities in the rat. Biochim Biophys Acta 1987; 922: 239-243.
110. Halminski M A, Marsh J B, Harrison E H. Differential effects of fish oil, safflower oil and palm oil on fatty acid oxidation and glycerolipid synthesis in rat liver. J Nutr 1991; 121: 1554-1561.
111. Surette M E, Whelan J, Broughton K S, Kinsella J E. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1992; 1126: 199-205.
112. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
113. Harris WS. Do ω̧3 fatty acids worsen glycemic control in NIDDDM? ISSFAL Newslett 1996; 3: 6-9.
114. Crary E J, McCarty M F. Potential clinical applications for high-dose nutritional antioxidants. Med Hypotheses 1984; 13: 77-98.
115. Kunisaki M, Bursell S-E, Clermont A C et al. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 1995; 269: E239-E246.
116. Aiello L P, Avery R L, Arrigg P G et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retino-pathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
117. Aiello L P, Northrup J M, Keyt B A et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-1544.
118. Hattori Y, Kasai K, Banba N et al. Effect of a phorbol ester on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Endocrinol Japon 1992; 39: 341-345.
119. Kohno M, Yokokawa K, Horio T et al. Release mechanism of endothelin-1 and big endothelin-1 after stimulation with thrombin in cultured porcine endothelial cells. J Vasc Res 1992; 29: 56-63.
120. Kuchan M J, Frangos J A. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 1993; 264: H150-H156.
121. Hollmann J, Schmidt A, von Bassewitz D-B, Buddecke E. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis 1989; 9: 154-158.
122. Wasty F, Alavi M Z, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993; 36: 316-322.
123. Kunisaki M, Bursell S-E, Umeda FJ et al. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels. Diabetes 1994; 43: 1372-1377.
124. Steinberg D. Antioxidants and atherosclerosis: a current assessment. Circulation 1991; 84: 1420-1425.
125. Princen H M G, van Poppel G, Vogelezang C et al. Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro: effect of cigarette smoking. Arterioscler Thromb 1992; 12: 554-562.
126. Jialal I, Grundy S M. Effect of combined supplementation with α-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. Circulation 1993; 88: 2780-2786.
127. Gilbert V A, Zebrowski E J, Chan A C. Differential effects of megavitamin E on prostacyclin and thromboxane synthesis in streptozotocin-induced diabetic rats. Hormone Metab Res 1983; 15: 320-325.
128. Kunisaki M, Umeda F, Inoguchi T, Nawata H. Vitamin E restores reduced prostacyclin synthesis in aortic endothelial cells cultured with a high concentration of glucose. Metabolism 1992; 41: 613-621.
129. Tran K, Chan A C. R,R,R-α-tocopherol potentiates prostacyclin release in human endothelial cells: evidence for structural specificity of the tocopherol molecule. Biochim Biophys Acta 1990; 1043: 189-197.
130. Pinksy M J. Treatment of intermittent claudication with alphatocopherol. J Am Pod Assoc 1980; 70: 454-458.
131. Petty M A, Kintz J, DiFrancesco G F. The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur J Pharmacol 1990; 180: 119-127.
132. Ristori M T, Verdetti J. Effects of taurine on rat aorta in vitro. Fund Clin Pharmacol 1991; 5: 245-258.
133. Franconi F, Giotti A, Manzini S et al. The effect of taurine on high potassium- and noradrenaline-induced contraction in rabbit ear artery. Br J Pharm 1982; 75: 605-612.
134. Goodnight S H. The effects of n-3 fatty acids on atherosclerosis and the vascular response to injury. Arch Pathol Lab Med 1993; 117: 102-106.
135. Gapinski J P, VanRuiswyk J V, Heudebert G R, Schectman G S. Preventing restenosis with fish oils following coronary angioplasty. Arch Intern Med 1993; 153: 1595-1601.
136. Renier G, Skamene E, DeSanctis J, Radzioch D. Dietary n-3 polyunsaturated fatty acids prevent the development of atherosclerotic lesions in mice: modulation of macrophage secretory activities. Arterioscler Thromb 1993; 13: 1515-1524.
137. Endres S, De Caterina R, Schmidt E B, Kristensen S D. n-3 polyunsaturated fatty acids: update 1995. Eur J Clin Invest 1995; 25: 629-638.
138. McCarty M F. Fish oil may be an antidote for the cardiovascular risk of smoking. Med Hypotheses 1996; 46: 337-347.
139. McGrath L T, Brennan G M, Donnelly J P et al. Effect of dietary fish oil supplementation on peroxidation of serum lipids in patients with non-insulin dependent diabetes mellitus. Atherosclerosis 1996; 121: 275-283.
140. Mustard J F, Packham M A. Editorial retrospective: platelets and diabetes mellitus. N Engl J Med 1984; 311: 665-667.
141. Davi G, Catalane I, Averna M et al. Thromboxane biosynthesis and platelet function in diabetes. N Engl J Med 1990; 322: 1769-1774.
142. Strano A, Davi G, Patrono C. In vivo platelet activation in diabetes mellitus. Semin Thromb Hemost 1991; 17: 422-425.
143. Franconi F, Bennardini F, Mattana A et al. Taurine levels in plasma and platelets in insulin-dependent and non-insulin dependent diabetes mellitus: correlation with platelet aggregation. In: Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 419-424.
144. Franconi F, Bennardini F, Mattana A et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 1995; 61: 1115-1119.
145. Kristensen S D, Schmidt E B, Dyerberg J. Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. J Intern Med 1989; 225(Suppl 1): 141-150.
146. Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 1992; 27: 533-538.
147. Simpson L O. Altered blood rheology in the pathogenesis of diabetic and other neuropathies. Muscle Nerve 1988; 11: 725-744.
148. 1 analogue TFC 612 on diabetic neuropathy in streptozotocin-induced diabetic rats: comparison with aldose reductase inhibitor ONO 2235. Diabetes 1989; 38: 832-838.
149. Malik R A, Masson E A, Sharma A K et al. Hypoxic neuropathy: relevance to human diabetic neuropathy. Diabetologia 1990; 33: 311-318.
150. Cameron N E, Cotter M A, Low P A. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991; 261: E1-E8.
151. Stevens M J, Feldman E L, Greene D A. The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects. Diab Med 1995; 12: 566-579.
152. + ATPase activity in rabbit aorta by hyperglycemia. J Clin Invest 1992; 90: 727-732.
153. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94: 853-859.
154. Bravenboer B, Kappelle A C, Hamers F P T et al. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia 1992; 35: 813-817.
155. Cameron N E, Cotter M A, Maxfield E K. Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 1993; 36: 299-304.
156. Packer L. Antioxidant properties of lipoic acid and its therapeutic effects in prevention of diabetes complications and cataracts. Ann NY Acad Sci 1994; 738: 257-264.
157. Sachse G, Williams B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Horm Metab Res Suppl 1980; 9: 105-107.
158. Verhage A H, Cheong W K, Jeejeebhoy K N. Neurologic symptoms due to possible chromium deficiency in long-term parenteral nutrition that closely mimic metronidazole-induced syndromes. JPEN 1996; 20: 123-127.
159. Jamal G A, Carmichael H, Weir A I. Gamma-linolenic acid in diabetic neuropathy. Lancet 1986; i: 1098.
160. The γ-Linolenic Acid Multicenter Trial Group. Treatment of diabetic neuropathy with γ-linolenic acid. Diabetes Care 1993; 16: 8-15.
161. Dines K C, Cotter M A, Cameron N E. Contrasting effects of treatment with ω̧-3 and ω̧-6 essential fatty acids on peripheral nerve function and capillarization in streptozotocindiabetic rats. Diabetologia 1993; 36: 1132-1138.
162. Pfeifer M A, Schumer M P. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44: 1355-1361.
163. Kilborn A, Wennmalm A. Endogenous prostaglandins as local regulators of blood flow in man: effect of indomethacin on reactive and functional hyperaemia. J Physiol 1976; 257: 109-121.
164. Vallance P, Collier J, Moncada S. Effects of endotheliumderived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii: 997-1000.
165. Cunnane S C, Manku M S, Horrobin D F. Abnormal essential fatty acid composition of tissue lipids in genetically diabetic mice is partially corrected by dietary linoleic and gammalinolenic acids. Br J Nutr 1985; 53: 449-458.
166. Mercuri O, Peluffo R O, Brenner R R. Depression of microsomal desaturation of linoleic to gamma-linolenic acid in the alloxan-diabetic rat. Biochim Biophys Acta 1966; 116: 409-411.